Abstract The Coronavirus Disease 2019 (COVID-19) pandemic has become a global crisis
and is more devastating than any other previous infectious disease. It has affected a …

Janus kinase (JAK) is a family of cytoplasmic non-receptor tyrosine kinases that includes
four members, namely JAK1, JAK2, JAK3, and TYK2. The JAKs transduce cytokine signaling …

Abstract The European Journal of Immunology was launched 50 years ago, coinciding with
the discovery of many cytokines and growth factors and the emergence of an entirely new …

The benefits of baricitinib in coronavirus disease‐2019 are inadequately defined. We
performed a systematic review and meta‐analysis of studies of baricitinib to determine its …

Abstract The 2019 coronavirus disease (COVID‐19) pandemic has become a global crisis.
In the immunopathogenesis of COVID‐19, SARS‐CoV‐2 infection induces an excessive …

We are witnessing a paradigm shift in drug development and clinical practice to fight the
novel coronavirus disease (COVID-19), and a number of clinical trials have been or are …

Purpose Hyperinflammation in severe COVID-19 infection increases the risk of respiratory
failure and one of the cogent reasons of mortality associated with COVID-19. Baricitinib, a …

Objectives This systematic review and meta-analysis of randomized controlled trials (RCTs)
aimed to investigate the clinical efficacy and safety of Janus kinase (JAK) inhibitors for …

Abstract Baricitinib is a Janus Kinase (JAK) inhibitor that is primarily used to treat moderately
to severely active rheumatoid arthritis in adults and has recently been reported for the …

Background There are conflicting reports on the results of several of the latest clinical trials
related to the use of baricitinib in the management of COVID-19 patients. The aim of the …